News Release: Seattle Gummy Company Receives Series A Investment from TLX Venture, an Investment Firm Led by Pharmaceutical and FDA Regulatory VeteransBy cwan | March 23rd, 2018
SEATTLE, Washington − Seattle Gummy Company (SGC), a Seattle Washington based nutraceutical and pharmaceutical company focusing on functional gummy formulations, has received an investment from TLX Venture in the company’s series A financing. TLX Venture, a New Jersey based investment firm, is led by a group of pharmaceutical and FDA regulatory veterans. The firm’s Managing Director, Dr. Tom Xie, has now joined SGC’s advisory board.
Dr. Xie is the founder and CEO of New Jersey based Brightech International (“Brightech”). Brightech was established in 2004 and grows to a full service CRO with over 100 staff members in US and China/Taiwan. Dr. Xie has over 24 years of clinical trial experience in pharmaceutical and CRO environments. Prior to founding the Brightech, he has gathered extensive pharmaceutical industry experience from companies including Arizona Cancer Center, Wyeth (a Pfizer Company), Johnson and Johnson and ImClone System (an Eli Lilly Company) holding positions from Sr. Statistician, Assistant Director and Associate Director. Dr. Xie is an expert in design of oncology trials and clinical data management. He has been helping companies from study design to FDA approvals and was an invited expert by China CFDA for drafting the Guidance for EDC Clinical Trials. He is also an active researcher with number of papers published in distinguished journals. Dr. Xie holds an adjunct assistant professor position at the Biostatistics Department at the School of Public Health of the Rutgers University, is a member of American Statistical Association, Drug Information Association, ASCO, Sino-America Statistical Association and an active journal reviewer for statistical journals.
SGC is currently raising Series A financing to aggressively expanding its gummy pharmaceutical products pipeline as well as its extensive intellectual property holdings in the gummy medicine space. The investment from TLX Venture will help to accelerate company’s new gummy drug development and approval process.
“We are excited to have Dr. Xie help us through FDA regulatory process with our novel gummy drug products,” said Dr. Connie Wan, the CEO of the company, “we are in the process of preparing the new drug application for our first gummy medicine — an allergy gummy. Having industrial veteran such as Dr. Xie to join us and help to guide us through the FDA process will greatly accelerate our gummy drug development and approval process.”
“We have been extremely impressed with the functional gummy technology that SGC has developed for gummy pharmaceutical products.” Said Dr. Xie, “We firmly believe in the potential of gummy medicine. Together, we will make SGC soar!”
About Seattle Gummy Company (SGC): SGC is an R&D focused developer and manufacturer of nutraceutical and pharmaceutical gummy products. The company specializes in formulating Functional Gummy® products combining the wealth of the in-house knowledge in pharmaceutics, organic chemistry, natural product chemistry, western medicine, and herbal medicine. The company provides performance focused nutraceutical supplements inspired by Traditional Chinese Medicine (TCM) that fit to each customer’s unique life style. The current TCM based nutraceutical product line includes MOCCA SHOTS™, ENERGON QUBE™, FUNTIONAL FRUIT®, and SEATTLE BEAUTY®. To learn more about SGC, visit https://seattlegummy.com.
About Brightech International: Brightech International, a CRO focused on clinical data solutions, provides high quality Biostatistics, SAS programming, Data Management, Medical Writing, Regulatory Strategy services since 2002. The company has the expertise, experience and excellent track records to support 25+ long-term clients. The company also provides specialty CDISC services and manages a sophisticated proprietary eClinical Suite (CIMS). To learn more about SGC, visit http://www.brightech-intl.com.